Trial reportPloS one2008
Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants.
Trial report in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Neonatal BCG Vaccination Reduces Interferon-γ Responsiveness to Heterologous Pathogens in Infants From a Randomized Controlled Trial.The Journal of infectious diseases · 2020Trial
- Trial
- A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.Journal of clinical immunology · 2013Trial
- A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses.PloS one · 2010Trial
- Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines.Research square · 2025Article
- Human alveolar macrophage response to Mycobacterium tuberculosis: immune characteristics underlying large inter-individual variability.Communications biology · 2025Article
- A systematic review and modelling insights of factors impacting measles vaccine effectiveness, efficacy and immunogenicity.Discover viruses · 2025Review
- Challenges in developing new tuberculosis vaccines.Memorias do Instituto Oswaldo Cruz · 2025Review
- Circulation ofPathogens and global health · 2019Review
- Factors That Influence the Immune Response to Vaccination.Clinical microbiology reviews · 2019Review
- The potential of the microbiota to influence vaccine responses.Journal of leukocyte biology · 2018Review
- Microphysiologic Human Tissue Constructs Reproduce Autologous Age-Specific BCG and HBV Primary ImmunizationFrontiers in immunology · 2018Article
- Mycobacterial L-forms are found in cord blood: A potential vertical transmission of BCG from vaccinated mothers.Human vaccines & immunotherapeutics · 2016Article
- Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled by Host Genotype.mBio · 2016Article
- The genetic regulation of infant immune responses to vaccination.Frontiers in immunology · 2015Review
- Effects of malnutrition on children's immunity to bacterial antigens in Northern Senegal.The American journal of tropical medicine and hygiene · 2014Article
- The Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosis.Frontiers in immunology · 2014Review
- Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology.Clinical and experimental immunology · 2012Review
- Article
- BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi.The Journal of infectious diseases · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundThere is a need for new vaccines for tuberculosis (TB) that protect against adult pulmonary disease in regions where BCG is not effective. However, BCG could remain integral to TB control programmes because neonatal BCG protects against disseminated forms of childhood TB and many new vaccines rely on BCG to prime immunity or are recombinant strains of BCG. Interferon-gamma (IFN-gamma) is required for immunity to mycobacteria and used as a marker of immunity when new vaccines are tested. Although BCG is widely given to neonates IFN-gamma responses to BCG in this age group are poorly described. Characterisation of IFN-gamma responses to BCG is required for interpretation of vaccine immunogenicity study data where BCG is part of the vaccination strategy. METHODOLOGY/PRINCIPAL
findings236 healthy Gambian babies were vaccinated with M. bovis BCG at birth. IFN-gamma, interleukin (IL)-5 and IL-13 responses to purified protein derivative (PPD), killed Mycobacterium tuberculosis (KMTB), M. tuberculosis short term culture filtrate (STCF) and M. bovis BCG antigen 85 complex (Ag85) were measured in a whole blood assay two months after vaccination. Cytokine responses varied up to 10 log-fold within this population. The majority of infants (89-98% depending on the antigen) made IFN-gamma responses and there was significant correlation between IFN-gamma responses to the different mycobacterial antigens (Spearman's coefficient ranged from 0.340 to 0.675, p = 10(-6)-10(-22)). IL-13 and IL-5 responses were generally low and there were more non-responders (33-75%) for these cytokines. Nonetheless, significant correlations were observed for IL-13 and IL-5 responses to different mycobacterial antigens CONCLUSIONS/SIGNIFICANCE: Cytokine responses to mycobacterial antigens in BCG-vaccinated infants are heterogeneous and there is significant inter-individual variation. Further studies in large populations of infants are required to identify the factors that determine variation in IFN-gamma responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.